Esperovax, Inc.

EGRESS

Vaccines; Oral vaccines; Modified cells for medical or clinical use; Pharmaceuticals in the nature of yeast-based pharmaceuticals; Oral vaccine preparations; Pharmaceutical products for the treatment of infectious diseases; Recombinant yeast-based pharmaceutical products; Yeast-based oral vaccines; Pharmaceutical preparations, namely, a drug delivery system comprising yeast-based oral vaccines; Pharmaceutical products, namely, yeast-based oral vaccines; Biological and pharmaceutical preparations, namely, recombinant yeast for medical use;

EGRESS RD

Vaccines; Oral vaccines; Modified cells for medical or clinical use; Pharmaceuticals in the nature of yeast-based pharmaceuticals; Oral vaccine preparations; Pharmaceutical products for the treatment of infectious diseases; Recombinant yeast-based pharmaceutical products; Yeast-based oral vaccines; Pharmaceutical preparations, namely, a drug delivery system comprising yeast-based oral vaccines; Pharmaceutical products, namely, yeast-based oral vaccines; Biological and pharmaceutical preparations, namely, recombinant yeast for medical use;

ESPEROFLU

Vaccines; Oral vaccines; Modified cells for medical or clinical use; Pharmaceuticals in the nature of yeast-based pharmaceuticals; Oral vaccine preparations; Pharmaceutical products for the treatment of infectious diseases; Recombinant yeast-based pharmaceutical products; Yeast-based oral vaccines; Pharmaceutical preparations, namely, a drug delivery system comprising yeast-based oral vaccines; Pharmaceutical products, namely, yeast-based oral vaccines; Biological and pharmaceutical preparations, namely, recombinant yeast for medical use;

ESPEROMAX

Biological preparations for the treatment of disease; Biological preparations, namely, proteins, for the treatment of disease; Biological preparations, namely, antibodies, for the treatment of disease; Biological preparations, namely, hormones, for the treatment of disease; Biological preparations, namely, preparations for use in the treatment of cancer, inflammation, and/or infectious disease;

ESPEROVAX

Vaccines; Oral vaccines; Modified cells for medical or clinical use; Pharmaceuticals in the nature of yeast-based pharmaceuticals; Oral vaccine preparations; Pharmaceutical products for the treatment of infectious diseases; Recombinant yeast-based pharmaceutical products; Yeast-based oral vaccines; Pharmaceutical preparations, namely, a drug delivery system comprising yeast-based oral vaccines; Pharmaceutical products, namely, yeast-based oral vaccines; Biological and pharmaceutical preparations, namely, recombinant yeast for medical use;Medical research in the field of vaccines and medicines; Research and development of vaccines and medicines; Research and development in the pharmaceutical and biotechnology fields; Scientific research in the field of vaccines and medicines; Pharmaceutical research and development; Research and development in the field of immunology; Research and development in the field of microorganisms, namely, research and development related to yeast; Research and development in the field of therapeutics; Development of pharmaceutical preparations and medicines; Scientific study and research in the field of medicine; Scientific study and research in the field of healthcare products; Medical and scientific research; Discovery, development and design of pharmaceutical and therapeutic preparations; Pharmaceutical, biologic, and vaccine research and development;

HERCRNA

Vaccines; Oral vaccines; Modified cells for medical or clinical use; Pharmaceuticals; Oral vaccine preparations; Pharmaceutical products for the treatment of infectious diseases; Recombinant yeast-based pharmaceutical products; Yeast-based oral vaccines; Pharmaceutical preparations, namely, a drug delivery system comprising yeast-based oral vaccines; Pharmaceutical products, namely, yeast-based oral vaccines; Biological and pharmaceutical preparations, namely, recombinant yeast for medical use; Medical, biological, and pharmaceutical preparations for medical use, namely, preparations containing messenger RNA for preventing infection, disease, or disorders; Medical, biological, and pharmaceutical preparations for medical use, namely, preparations containing messenger RNA for treating infection, disease, or disorders; mRNA-based therapeutics and therapeutic agents for in vivo, ex vivo, or in situ prevention of infection, disease, or disorders; mRNA-based therapeutics and therapeutic agents for in vivo, ex vivo, or in situ treatment of infection, disease, or disorders;

VS TECHNOLOGY

Vaccines; Oral vaccines; Modified cells for medical or clinical use; Pharmaceuticals in the nature of yeast-based pharmaceuticals; Oral vaccine preparations; Pharmaceutical products for the treatment of infectious diseases; Recombinant yeast-based pharmaceutical products; Yeast-based oral vaccines; Pharmaceutical preparations, namely, a drug delivery system comprising yeast-based oral vaccines; Pharmaceutical products, namely, yeast-based oral vaccines; Biological and pharmaceutical preparations, namely, recombinant yeast for medical use;TECHNOLOGY;Medical research in the field of vaccines and medicines; Research and development of vaccines and medicines; Research and development in the pharmaceutical and biotechnology fields; Scientific research in the field of vaccines and medicines; Pharmaceutical research and development; Research and development in the field of immunology; Research and development in the field of microorganisms, namely, research and development related to yeast; Research and development in the field of therapeutics; Development of pharmaceutical preparations and medicines; Scientific study and research in the field of medicine; Scientific study and research in the field of healthcare products; Medical and scientific research; Discovery, development and design of pharmaceutical and therapeutic preparations; Pharmaceutical, biologic, and vaccine research and development;